#VisualAbstract: Daratumumab Reduces Risk of Progression in High-Risk Smoldering Multiple Myeloma
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Tag: daratumumab
Daratumumab linked to improved progression-free survival and MRD-negativity in transplant-eligible myeloma patients
1. Daratumumab in combination with bortezomib, thalidomide, and dexamethasone (D-VTd) as induction and consolidation therapy led to superior progression-free survival ...
Subcutaneous daratumumab with VRd improves progression-free survival in multiple myeloma
1. Adding subcutaneous daratumumab to VRd (bortezomib, lenalidomide, and dexamethasone) induction/consolidation, and lenalidomide maintenance therapy improves progression-free survival in eligible ...
#VisualAbstract: Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed ...
Daratumumab therapy addition improved response in systemic immunoglobulin light-chain amyloidosis
1. Daratumumab therapy addition to bortezomib, cyclophosphamide, and dexamethasone showed improved cancer response in patients with systemic immunoglobulin light-chain amyloidosis. ...
#VisualAbstract CASSIOPEIA Part 1: Bortezomib, Thalidomide, and Dexamethasone with Daratumumab (D-VTd) May Improve Quality of Life Post-Consolidation in Newly Diagnosed, Transplantation-Eligible Multiple Myeloma (MM) Patients
Check out the original article from the Lancet Haematology here.
